Skip to Content

Kyprolis (carfilzomib) Disease Interactions

There are 11 disease interactions with Kyprolis (carfilzomib):

Major

Carfilzomib (Includes Kyprolis) ↔ Tls

Severe Potential Hazard, Moderate plausibility

Applies to: Tumor Lysis Syndrome

Cases of tumor lysis syndrome (TLS), including fatal outcomes, have been reported in patients receiving carfilzomib. Patients with multiple myeloma and a high tumor burden should be considered at a greater risk for TLS. Ensure that patients are well hydrated before administration of therapy in Cycle 1, and in subsequent cycles as recommended by the manufacturer. Consider uric acid-lowering drugs in patients at risk for TLS. It is recommended to monitor for evidence of TLS during treatment and manage promptly, including interruption of therapy until resolution of TLS.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Cardiac Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Heart Disease

Carfilzomib can cause new onset or worsening of preexisting cardiac failure, restrictive cardiomyopathy, myocardial ischemia, and myocardial infarction. Patients with preexisting heart problems might be at a greater risk of cardiac toxicity. It is recommended to monitor patients for clinical signs or symptoms of cardiac failure or cardiac ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold therapy for Grade 3 or 4 cardiac adverse events until recovery, and consider whether to restart at 1 dose level reduction based on a benefit/risk assessment.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Dyspnea

Moderate Potential Hazard, Moderate plausibility

Applies to: Heart Disease, Pulmonary Impairment

Dyspnea was reported in patients treated with carfilzomib. Evaluate dyspnea to exclude cardiopulmonary conditions including cardiac failure and pulmonary syndromes. Withhold therapy with carfilzomib for Grade 3 or 4 dyspnea until resolved or returned to baseline. Consider whether to restart therapy based on a benefit/risk assessment.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Hemorrhage

Moderate Potential Hazard, Moderate plausibility

Applies to: Bleeding, Thrombocytopenia

Fatal or serious cases of hemorrhage have been reported in patients treated with carfilzomib. Hemorrhage has been reported in patients having either low or normal platelet counts. Hemorrhage has also been reported in patients who were not on antiplatelet therapy or anticoagulation. Care should be exercised when using this agent in patients at risk of hemorrhagic events. Promptly evaluate signs and symptoms of blood loss. It is recommended to monitor platelet counts frequently during treatment and to reduce or withhold dose as appropriate.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Hepatic Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Cases of hepatic failure, including fatal cases, have been reported in patients receiving treatment with carfilzomib. The pharmacokinetics and safety of carfilzomib were evaluated in patients with normal hepatic function, or mild, moderate, or severe hepatic impairment. The AUC of carfilzomib increased by approximately 50% in patients with mild and moderate hepatic impairment compared to patients with normal hepatic function. PK data were not collected in patients with severe hepatic impairment. It is recommended to reduce the dose of carfilzomib by 25% in patients with mild or moderate hepatic impairment. Dosing recommendation cannot be made for patients with severe hepatic function. Monitor liver enzymes regularly, regardless of baseline values, and modify dose based on toxicity. Therapy with this agent can cause increased serum transaminases. Monitor liver enzymes regularly, regardless of baseline values. It is recommended to reduce or withhold dose as appropriate.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Hypertension

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypertension

The use of carfilzomib has been associated with hypertension, including hypertensive crisis and hypertensive emergency. It is recommended to monitor blood pressure regularly in all patients, especially in hypertensive patients. Care should be taken and if hypertension cannot be adequately controlled, withhold therapy and consider whether to restart therapy based on a benefit/risk assessment.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Pres

Moderate Potential Hazard, Moderate plausibility

Applies to: Posterior Reversible Encephalopathy Syndrome

Cases of posterior reversible encephalopathy syndrome (PRES) have been reported with the use carfilzomib. Discontinue therapy if PRES is suspected and evaluate. Care should be exercised as the safety of reinitiating carfilzomib therapy in patients previously experiencing PRES is not known.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Pulmonary Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Pulmonary Impairment

The use of carfilzomib has been associated with pulmonary toxicity. Patients presenting pulmonary symptoms should be carefully assessed for pulmonary toxicity. It is recommended to discontinue treatment in the event of drug-induced pulmonary toxicity.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Renal Failure

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Cases of acute renal failure have occurred in patients receiving carfilzomib. The risk was greater in patients with a baseline reduced estimated creatinine clearance. It is recommended to monitor renal function with regular measurement of the serum creatinine and/or estimated creatinine clearance. Consider reducing or withholding dose as appropriate.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Ttp/Hus

Moderate Potential Hazard, Moderate plausibility

Applies to: Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura

Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) have been reported with the use of carfilzomib. Monitor for signs and symptoms of TTP/HUS. If the diagnosis is suspected, stop therapy and evaluate patients. If the diagnosis of TTP/HUS is excluded, therapy may be restarted. The safety of reinitiating carfilzomib therapy in patients previously experiencing TTP/HUS is not known.

Moderate

Carfilzomib (Includes Kyprolis) ↔ Venous Thrombosis

Moderate Potential Hazard, Moderate plausibility

Applies to: Pulmonary Embolism, History - Thrombotic/Thromboembolic Disorder, Thrombotic/Thromboembolic Disorder

Carfilzomib should be used with caution in patients with a history of venous thromboembolic events, including deep venous thrombosis and pulmonary embolism. Thromboprophylaxis is recommended for patients being treated with the combination of carfilzomib with dexamethasone or with lenalidomide plus dexamethasone. The thromboprophylaxis regimen should be based on an assessment of the patient's underlying risks. Patients using oral contraceptives or a hormonal method of contraception associated with a risk of thrombosis should consider an alternative method of effective contraception during treatment with carfilzomib in combination with dexamethasone or lenalidomide plus dexamethasone.

Kyprolis (carfilzomib) drug Interactions

There are 296 drug interactions with Kyprolis (carfilzomib)

Kyprolis (carfilzomib) alcohol/food Interactions

There is 1 alcohol/food interaction with Kyprolis (carfilzomib)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide